secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-07-19T23:59:59+00:00
Accession:  0001493152-24-028443
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré regains Nasdaq minimum bid price compliance, delisting risk removed
------------------------------------------------------------------------

- Nasdaq notified Daré that closing bid price was ≥$1.00 for 10 consecutive sessions; compliance achieved.
- Regaining compliance avoids potential delisting from Nasdaq Capital Market, strengthening market position.
- Enrolling participants in pivotal Phase 3 study of Ovaprene for hormone-free monthly contraceptive candidate.
- Continuing activities to progress Sildenafil Cream 3.6% Phase 3 pivotal studies for female sexual arousal disorder.
- Awaiting additional FDA feedback on endpoints and safety database requirements for NDA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224028443/0001493152-24-028443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224028443/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer